The Valley Desk

NCT02729025 · Interventional trial

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))

Overall registry status Completed

Phase 3

Conditions Subjects With Hyperlipidemia, Dyslipidemia

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov